Form D · Biotechnology
GnuBIO Inc.
Cambridge, MA · CIK 0001506709
Offering snapshot reported Oct 2, 2012 · SEC filing
- Reported sold
- $10M Offering amount: $10M
- Investors reported
- 22 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 28, 2012 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 2, 2012 | Initial | $10,000,000 | No comparison | 22 | SEC filing |
| Sep 6, 2011 | Amendment | $8,000,000 | $5,000,000vs Dec 2, 2010 | 12 | SEC filing |
| Dec 2, 2010 | Initial | $3,000,000 | No comparison | 12 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0 (estimated)
- Finders' fees
- $0 (estimated)
- Form D file number
- 021-184878
Source: Form D, filed Oct 2, 2012. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Marie Claude Bernal | Director |
| Marie Claude Bernal | Director |
| David Bianchi | Director |
| John Boyce | Director, Executive |
| Boyce John | Director, Executive, Promoter |
| David Weitz | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1 Kendall Square, Bldg. 1400 Suite 14201
Cambridge, MA, 02139
Cambridge, MA, 02139